-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ATyr Pharma (NASDAQ:LIFE) Lowered to Sell at StockNews.com
ATyr Pharma (NASDAQ:LIFE) Lowered to Sell at StockNews.com
aTyr Pharma (NASDAQ:LIFE – Get Rating) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Wednesday.
LIFE has been the topic of several other research reports. HC Wainwright lifted their price target on shares of aTyr Pharma from $11.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, July 21st. Piper Sandler upped their target price on shares of aTyr Pharma from $11.00 to $14.00 and gave the stock an "overweight" rating in a report on Monday, August 15th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to data from MarketBeat, aTyr Pharma currently has a consensus rating of "Moderate Buy" and an average price target of $22.75.
Get aTyr Pharma alerts:aTyr Pharma Trading Down 7.3 %
aTyr Pharma stock traded down $0.27 during trading on Wednesday, reaching $3.42. The company had a trading volume of 128,653 shares, compared to its average volume of 132,376. The firm's 50-day simple moving average is $3.48 and its 200 day simple moving average is $3.82. aTyr Pharma has a 52 week low of $2.60 and a 52 week high of $13.10. The firm has a market capitalization of $97.90 million, a price-to-earnings ratio of -2.12 and a beta of 1.49.
aTyr Pharma (NASDAQ:LIFE – Get Rating) last posted its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). During the same period in the previous year, the company earned ($0.64) earnings per share. On average, analysts predict that aTyr Pharma will post -1.81 earnings per share for the current year.Insider Activity
In related news, CEO Sanjay Shukla purchased 15,000 shares of aTyr Pharma stock in a transaction on Friday, July 1st. The shares were bought at an average cost of $2.88 per share, for a total transaction of $43,200.00. Following the acquisition, the chief executive officer now owns 40,798 shares in the company, valued at approximately $117,498.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.36% of the company's stock.
Hedge Funds Weigh In On aTyr Pharma
Several institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in aTyr Pharma during the second quarter valued at $29,000. D.A. Davidson & CO. purchased a new stake in shares of aTyr Pharma during the 2nd quarter valued at about $31,000. Qube Research & Technologies Ltd purchased a new stake in shares of aTyr Pharma during the 4th quarter valued at about $87,000. Virtu Financial LLC bought a new position in shares of aTyr Pharma in the 1st quarter valued at about $70,000. Finally, Raymond James & Associates bought a new stake in aTyr Pharma during the fourth quarter worth approximately $184,000. Hedge funds and other institutional investors own 65.58% of the company's stock.
aTyr Pharma Company Profile
(Get Rating)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Recommended Stories
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- It's Time To Embrace Another 25% Decline In The S&P 500
- Is Five Below Trying to Punch Too High?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
aTyr Pharma (NASDAQ:LIFE – Get Rating) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Wednesday.
在週三發佈的一份研究報告中,斯托克新聞網的投資分析師將aTyr Pharma(納斯達克:LIFE-GET評級)的評級從持有下調至賣出。
LIFE has been the topic of several other research reports. HC Wainwright lifted their price target on shares of aTyr Pharma from $11.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, July 21st. Piper Sandler upped their target price on shares of aTyr Pharma from $11.00 to $14.00 and gave the stock an "overweight" rating in a report on Monday, August 15th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to data from MarketBeat, aTyr Pharma currently has a consensus rating of "Moderate Buy" and an average price target of $22.75.
生活一直是其他幾份研究報告的主題。在7月21日星期四的一份報告中,HC Wainwright將aTyr Pharma的股票目標價從11.00美元上調至35.00美元,並給予該公司“買入”評級。派珀·桑德勒在8月15日週一的一份報告中將aTyr Pharma的目標價從11.00美元上調至14.00美元,並給予該股“增持”評級。一名分析師對該股的評級為賣出,四名分析師對該公司股票的評級為買入。根據MarketBeat的數據,aTyr Pharma目前的共識評級為“中等買入”,平均目標價為22.75美元。
aTyr Pharma Trading Down 7.3 %
ATyr Pharma股價下跌7.3%
aTyr Pharma stock traded down $0.27 during trading on Wednesday, reaching $3.42. The company had a trading volume of 128,653 shares, compared to its average volume of 132,376. The firm's 50-day simple moving average is $3.48 and its 200 day simple moving average is $3.82. aTyr Pharma has a 52 week low of $2.60 and a 52 week high of $13.10. The firm has a market capitalization of $97.90 million, a price-to-earnings ratio of -2.12 and a beta of 1.49.
在週三的交易中,aTyr Pharma的股價下跌了0.27美元,達到3.42美元。該公司的成交量為128,653股,而其平均成交量為132,376股。該公司的50日簡單移動均線切入位為3.48美元,200日簡單移動均線切入位為3.82美元。ATyr Pharma的52周低點為2.60美元,52周高點為13.10美元。該公司市值為9790萬美元,市盈率為-2.12倍,貝塔係數為1.49。
Insider Activity
內幕活動
In related news, CEO Sanjay Shukla purchased 15,000 shares of aTyr Pharma stock in a transaction on Friday, July 1st. The shares were bought at an average cost of $2.88 per share, for a total transaction of $43,200.00. Following the acquisition, the chief executive officer now owns 40,798 shares in the company, valued at approximately $117,498.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.36% of the company's stock.
在相關新聞中,首席執行官桑賈伊·舒克拉在7月1日(星期五)的一筆交易中購買了15,000股aTyr Pharma股票。這些股票是以每股2.88美元的平均價格購買的,總交易額為43,200.00美元。收購完成後,這位首席執行官現在擁有該公司40,798股股票,價值約117,498.24美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過美國證券交易委員會網站獲得。公司內部人士持有該公司4.36%的股份。
Hedge Funds Weigh In On aTyr Pharma
對衝基金參與aTyr Pharma
Several institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in aTyr Pharma during the second quarter valued at $29,000. D.A. Davidson & CO. purchased a new stake in shares of aTyr Pharma during the 2nd quarter valued at about $31,000. Qube Research & Technologies Ltd purchased a new stake in shares of aTyr Pharma during the 4th quarter valued at about $87,000. Virtu Financial LLC bought a new position in shares of aTyr Pharma in the 1st quarter valued at about $70,000. Finally, Raymond James & Associates bought a new stake in aTyr Pharma during the fourth quarter worth approximately $184,000. Hedge funds and other institutional investors own 65.58% of the company's stock.
幾家機構投資者最近增持或減持了該公司的股份。簡街集團在第二季度購買了aTyr Pharma的一個新頭寸,價值2.9萬美元。D.A.Davidson&Co.在第二季度購買了aTyr Pharma的新股份,價值約31,000美元。Qube Research&Technologies Ltd在第四季度購買了aTyr Pharma的新股份,價值約8.7萬美元。Virtu Financial LLC在第一季度購買了aTyr Pharma的新頭寸,價值約7萬美元。最後,Raymond James&Associates在第四季度購買了aTyr Pharma的新股份,價值約為18.4萬美元。對衝基金和其他機構投資者持有該公司65.58%的股票。
aTyr Pharma Company Profile
ATyr製藥公司簡介
(Get Rating)
(獲取評級)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
ATyr Pharma,Inc.是一家生物療法公司,在美國從事基於新免疫途徑的藥物的發現和開發。該公司的主要候選藥物是efzofitimod,這是一種NRP2的選擇性調節劑,正在進行肺結節病的第二階段臨牀試驗;以及1b/2a階段的臨牀試驗,用於治療其他間質性肺部疾病,如慢性過敏性肺炎和與ILD相關的結締組織疾病。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- It's Time To Embrace Another 25% Decline In The S&P 500
- Is Five Below Trying to Punch Too High?
- 免費獲取StockNews.com關於aTyr Pharma(LIFE)的研究報告
- 具有有趣內幕活動的四隻廉價股票
- 健康飲料製造商Celsius能否超越其Monster競爭對手?
- 隨着收購傳言的甚囂塵上,Lyft能否成功?
- 現在是時候接受標準普爾500指數再下跌25%的時候了
- 下面的五個是不是打得太高了?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受aTyr Pharma Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對aTyr Pharma和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧